The unprecedent situation resulting from the COVID-19 pandemic impacts the ability to conduct clinical trials on a global scale. Pharmaceutical companies need to address multiple challenges to ensure the continuity of trials on human medicines. Many countries have introduced local lockdown measures, which affect trial site accessibility. In addition, limited availability of medical staff and disruptions in global supply chain raise questions around the provision of investigational medicinal products (IMPs) or modifications to clinical trials protocols.